Bioequivalence Study of Two Formulatiosns With the Asscociaton of Efavirenz, Emtricitabine and Tenofovir
Status:
Completed
Trial end date:
2017-02-28
Target enrollment:
Participant gender:
Summary
Bioequivalence study of two formulations containing a fixed dose combination of 600 mg
Efavirenz, 200 mg Emtricitabine and 300 mg Tenofovir Disproxyl Fumarate in coated tablets
under a single-dose, two-way crossover design.
Phase:
Phase 4
Details
Lead Sponsor:
Laboratorio Elea Phoenix S.A. Laboratorio Elea S.A.C.I.F. y A.
Treatments:
Efavirenz Emtricitabine Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Tenofovir